## Abstract The symposium will consist of current issues in genetic and environmental contributions to Parkinson's disease and other movement disorders with peerβreviewed platform and poster presentations designed to communicate recent research advances, including new pharmacological and nonβpharma
Program: Twenty Third Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 132 KB
- Volume
- 24
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
The symposium will consist of two keynote speakers and peerβreviewed platform and poster presentations designed to communicate recent research advances, including new pharmacological and nonβpharmacological treatment options, in the field of Parkinson's disease, Huntington disease, ataxia, dystonia, myoclonus, Tourette's syndrome, Essential Tremor and other movement disorders thereby enhancing patient care. Professionals in neurology and related disciplines as well as practitioners, psychologists, educators, and researchers are invited to attend. The gaps in clinical practice we wish to address are the unmet needs pertaining to the translational and clinical evaluation, along with the care and treatment of patients and families affected by Parkinson's disease and other movement disorders.
At the conclusion of this session, participants should be able to: 1) Identify and describe by scholarly review, oral presentation and group discussion the current research into the diagnosis, prevention and treatment of Parkinson's disease (PD) and Essential Tremor (ET) which may be relevant to current treatment or which may lead to the development of further research protocols; 2) Distinguish and assess the important advances in research and clinical treatments relating to Parkinson's disease and Essential Tremor in terms of available treatment options or new methodologies for clinical research; 3) Explain new pharmacological and nonβpharmacological treatment options available for Parkinson's disease and other movement disorders in connection with their clinical practice or with regard to further clinical research methods; 4) Interpret the mechanisms (genetic, environmental, pathophysiology, neurobiology) linked to Parkinson's disease and other movement disorders when assessing Parkinson's disease or other movement disorder patients or when developing new research protocols; and 5) Employ diagnostic approaches and tools available for assessing Parkinson's disease and Essential Tremor when diagnosing new patients or when conducting clinical research.
π SIMILAR VOLUMES
## Abstract This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of The Movement Disorder Society and The Parkinson Study Group. The Movement Disorder Societ
The morning session will focus on the Etiology, Pathogenesis, and Treatment of Parkinson's Disease. It consists of a keynote speaker and 10 presentations by the following individuals with allotted time for questions and answers after each presenter.
## Abstract Cosponsored by the Parkinson Study Group, Huntington Study Group, Dystonia Study Group, Myoclonus Study Group, Tourette's Syndrome Study Group, Cooperative Ataxia Group, and the Movement Disorder Society.
The morning session consists of a keynote speaker and 11 presentations by the following individuals with allotted time for questions and answers after each presenter.